Dr. Joseph Arboleda-Velasquez
I'm a scientist, physician, mentor, teacher, and entrepreneur interested in advancing understanding and promoting resistance to neurodegeneration in Alzheimer's disease and in small vessel diseases of the brain and the retina.
MY LATEST RESEARCH
Therapeutic antibody targeting of Notch 3 signaling prevents mural cell loss in CADASIL
​
- Using an in vivo model of CADASIL we discovered that activating Notch 3 signaling is a viable modality of treatment to prevent vascular degeneration.
- Using the same model, we validated some of the blood biomarkers that we previously reported, which we hope can be use in future clinical trials
(You can download the full article by clicking on the Read More tab below)
Blood biomarkers of CADASIL
​
- Using an in vivo model of CADASIL we identified Notch 3, endostatin, and HTRA1 as potential blood biomarkers.
- In our model, these changes in blood biomarkers correlate with a robust loss of vascular smooth muscle cells in the retina shown in figure above.